Submit manuscript...
eISSN: 2572-8474

Nursing & Care Open Access Journal

Opinion Volume 11 Issue 3

Suicide study, past progress and diagnostic transition

Da Yong Lu

School of Life Science, Shanghai University, China

Correspondence: Da Yong Lu, School of Life Sciences, Shanghai University, Shanghai 200444, PRC, China

Received: May 21, 2025 | Published: July 17, 2025

Citation: Lu DY. Suicide study, past progress and diagnostic transition. Nurse Care Open Acces J. 2025;11(3):75-77. DOI: 10.15406/ncoaj.2025.11.00323

Download PDF

Abstract

Human suicide is a dangerous phenomenon causing 0.5-1.2 million human mortality annually worldwide. Due to complex features, human suicide study is in a high demand now. Abundant of money and human resources are allocated for developing systems of human suicide prediction, preventions and useful countermeasure. To implement this noteworthy subject, biomedical study is indispensable. Historically, suicide knowledge was greatly based on mental illness study. From long standing suicide and mental disorder relation, the knowledge accumulation and distributions have been evolving mutually. Yet, diagnostic and therapeutic study is almost less advanced in mortality reduction. No 100% effective therapeutics has been dependent. To change this scenario, different fields of suicide studies are discussed.

Keywords: suicide, psychiatric disease, diagnostics, mental illness

Introduction

Overall scenario

Human suicide is a mystery process for inducing 1.3% human deaths.1-3 Due to many undiscovered character, human suicide biological investigation is critical. In addition to life and economic loses, advanced suicide prediction, prevention and medical management systems should be established.3-7

Risk factors

Many risk factors can lead to human suicide.3-7 Human mental health problems (mood disorder, affective diseases, depressive disorders, schizophrenia and so on) have just been discovered to associate with human suicide and deaths. Scientific study of mental illness and other risk factors should be explored for new knowledge enrichments.

Early history

Knowledge evolution

Suicide reports have been lasting from era of Hippocrates (460-377 BC).8-12 The diagnostic and therapeutic studies were evolving in different angels. Table 1 yet, the controversies and challenge of these areas remain. No effective drugs and therapies were popular in the clinic. To face with this dilemma, past reports and literatures should be reevaluated.

Timeline

Major discovery

Ancient Greece

Four elements and melancholy (excess of black bile)

Aretaeus of Cappadocia

Clinical feature of depressive

Middle age

Patients with delusion

16th to 17th

Clinical diagnosis & behavior abnormal

18th

Nervous (animal spirits)

19th

Psychiatric symptoms

20th

Mood disorder & electroplexy & psychosurgery

Table 1 Historic order of suicide knowledge changes

Methodology

Human suicide causality is arguable and complex. Today, neuropsychiatric factors and techniques of genomics and molecular biology are noticeable for suicide diagnosis and treatment.13-17 Table 2 shows overall relation and methods between suicide and mental disorders. From the general diagnostics and suicide risks are similar between mood disorders or others (hopeless feeling, self-blame and so on) and genetic alteration (poly-genic). The outside stresses (marriage problems and job/family member losses) are also identical between mood disorders and suicide.18-21

Worldwide; totally 15,629 cases

UK; totally 4,859 cases

Mood disorders

35%

Mood disorders

42%

Substance disorders

22%

Schizophrenia

20%

Personality disorders

12%

Personality disorders

11%

Schizophrenia

11%

Alcohol dependent

9%

Anxiety disorders

6%

Drug dependent

4%

   

Anxiety disorders

3%

Other disorders

14%

Other disorders

11%

Table 2 The statistics between suicide and other diseases8

Genomic studies

The biomedical studies of human diseases and suicide needs high-quality of suicide prediction, preventions and therapeutics.18, 22-26 It advanced greatly in genetic and molecular scenarios. The biomedical information of mental healthcare problems can be translated to high-quality suicide prediction, prevention and therapeutics.

Mental disease pathogenesis

Mental disorders has high rate of human deaths worldwide. In Hippocrates era, “melancholia”—today “depression” (Unipolar disorder) was reported in ancient records. More recently, these mindsets had been lasted. The core of this mindsets can be further helpful in scientific and medical investigations in the future. The explorations of suicide and mental illness last to nowadays. However, the molecular diagnostics are just begun to flourish. Modern diagnostics (genes or molecular) is a new trend.17-21 Human suicides were reported to be controlled by drugs, such as antidepressants.18-21 However, it has both benefits and risks.26 The improved therapeutics should be discovered.

Current achievements in diagnostics

Psychiatric reviews

The diagnostic guidelines vary Diagnostic and Statistical Manual between mental disorder and suicide. There are many similarities between two systems. Some further studies and streamlines should be made. This form of diagnostic system is the cornerstone of past learning.

Diagnostic insights

Psychiatrics is popular for clinicians or psychiatrists—score or rating for patients. Genetic platforms, like as pharmacogenomics (PG), sequencing, multi-omics or brain image are new frontiers to progress. The analysis of human behaviors mask the disease originations in genetics. The brain features of morphological or visual changes or abnormality see promising outcome in general hospitals and current trends.17-21 The genetic changes in many genes are under evaluations.22-23 At least 40 human genes are reported in human suicide. Many scientific research and challenge should be addressed in future.

Neuropathy and brain image

To establish new suicide diagnostic platforms, brain image study is the key and popular now.25-31 These complex processes have been investigating for two decades (four-fold increase in article number since 2005).32 A number of structural or functional variations have been identified. This is the fastest developing discipline is neuropsychiatric and suicide studies.

Clinical highlights

The progress of suicide studies is rapidly.33-36 Some antidepressants, especially selective serotonin reuptake inhibitor, SSRI show favorable outcomes in the clinic. In addition to antidepressants, other therapeutic selections, such as light therapy (physical treatment),37 emotional regulation,38 education for teenage39 are also useful for suicide reduction.

Mathematics and computation

Mathematics or computation (artificial intelligence, AI) are playing important role. Mathematics methods or equation can increase way or latitude of problem thinking.40-41 AI can simply these research and clinical application.42-44

Modern challenges

Genetic- or molecular-based suicide prediction and prevention system are future trends. After these studies, patient diagnostics will be quicker and low costs. Drug therapeutics can be highly effective, personalized and usefulness. Investigational pathways are discussed as

  1. Biology, scoring and computational systems help clinical treatments
  2. Different algorithm or calculation systems for customizing several workable paradigms for individual patients
  3. Establishing new diagnosis and treatments by modern technology (genetic, molecular and brain image)
  4. Collecting more biology and pathology data in the clinic.
  5. Accumulating treatment data for future referencing (big-data processing) (Figure 1).

Figure 1 Possible diagram of suicide/mental disorder diagnostic evolutions.

Results

To implement this noteworthy subject, biomedical study is indispensable. Historically, suicide knowledge was mainly based on mental illness study. From long standing suicide and mental disorder relation, the knowledge accumulation and distributions have been evolving mutually.

Discussion

A lot of knowledge and therapies in suicide studies (comorbid, suicide arms, genomics, molecular biology and risk factors) have been revealed across history. Medical solution should be translated from past studies.

Conclusion

Yet, diagnostic and therapeutic study is almost less advanced in mortality reduction. No 100% effective therapeutics has been dependent. To change this scenario, other fields of suicide studies should be aimed. Human suicidal study and application is very important in the clinic. Many comparison between patients and normal people is highly required. This kind of knowledge, diagnosis, and treatment improvement may possibly save many lives and make this world more harmonies.

Acknowledgments

None.

Conflicts of interest

None.

References

  1. Flach R, Fodor R, Kettel-Fulop F, et al. Myths about suicide—validating the Hungarian version of the Literacy of Suicide Scale (H-LOSS) on a community sample. BMC Public Health. 2024;24:2351.
  2. Chahla MNA, Khalil M, Comai S, et al. Biological factors underpinning suicidal behavior: an update. Brain Sci. 2023;13:505.
  3. Lu DY. Suicide Risks and Treatments: New Ideas and Future Perspectives. New York, NY: Nova Science Publishers; 2017.
  4. Serafini G, Salano P, Amore M. Suicidal ideation: a comprehensive overview. In: Weaver B, ed. Suicidal Ideation: Predictors, Prevalence and Prevention. New York, NY: Nova Science Publishing; 2015:1–42.
  5. Lu DY, Lu TR, Lu Y, et al. Introduction for suicide study. J Metab Syndr. 2017;6(2):227.
  6. Lu DY. Human suicide, biomedical knowledge and therapeutic advances. Hosp Palliat Med Int J. 2024;7(3):92–94.
  7. Lu DY, Wu HY, Lu TR. Human suicide: an overview of management strategies. J Clin Med Rev. 2024;3(2):1–6.
  8. Marreros A. Mood disorders: epidemiology and natural history. Psychiatry. 2008;8(2):52–55.
  9. Shandilya S. Suicide and suicide prevention: a historical review. Res J Soc Sci. 2018;9(12):35–40.
  10. Lu DY, Wu HY, Cao S, et al. Historical analysis of suicide. J Transl Genet Genom. 2020;4:33.
  11. Lu DY, Zhu PP, Wu HY, et al. Human suicide study: is there an association between suicide and mental illness? Metabolomics. 2016;6(3):186.
  12. Davison K. Historical aspects of mood disorders. 2006;5(4):115–118.
  13. While D, Bickley H, Roscoe A, et al. Implementation of mental health service recommendations in England and Wales and suicide rates, 1997–2006: a cross-sectional and before-and-after observational study. 2012;379:1005-1012.
  14. Desmyter S, Bijttebier S, van Heeringen K. The role of neuroimaging in our understanding of the suicidal brain. CNS Neurol Disord Drug Targets. 2013;12(7):921–929.
  15. Lu DY, Lu TR, Yarla NS, et al. Genetics in suicide treatments, modern diagnosis establishments. J Ment Disord Treat. 2017;3(2):145.
  16. Kendell R. Diagnosis and classification of mood disorders. Psychiatry. 2006;5(4):112–114.
  17. Lu DY, Lu TR, Che JY, et al. Genetics and bioinformatics studies of antidepressant drug therapeutic efficacies and toxicities: a current overview. Recent Pat CNS Drug Discov. 2014;9(3):193–199.
  18. Lu DY. Human suicide: clinical treatment overview. J Psychol Clin Psychiatry. 2025;16(1):24–28.
  19. Polo EP, Odife OA, Elusiyan TF. Utilitarian in suicide: insights from Freudian-Durkheimian theories and the response of Christian ethics. Nnadiebube J Soc Sci. 2025;5(1):39–50.
  20. Lu DY, Lu TR, Zhu PP, et al. The efficacies and toxicities of antidepressant drugs in clinics: building the relationship between chemo-genetics and socio-environments. CNS Agents Med Chem. 2016;16(1):12–18.
  21. Lu DY, Wu HY. Neuropsychiatric insights for human suicide. Int J Sci Res Updates. 2021;1(2):11–18.
  22. Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell. 2012;148:1223-1241.
  23. Krystal JH, State MW. Psychiatric disorders: diagnosis to therapy. Cell. 2014;157:201–214.
  24. Lu DY, Wu HY. Neuropsychiatric approaches for human suicide prediction and management. Int J Neuropsychol Behav Sci. 2021;2(3):87–91.
  25. Lu DY, Wu HY, Xu B, et al. Neurobiology for human suicide. Int J Sci Res Arch. 2021;2(2):120–125.
  26. Desmyter S, Bijttebier S, van Heeringen K. The role of neuroimaging in our understanding of the suicidal brain. CNS Neurol Disord Drug Targets. 2013;12(7):921–929.
  27. Lu DY, Lu TR, Zhu PP. Undesired neural side-effects of a drug: a chemical and genetic interrelated problem. CNS Agents Med Chem. 2010;10(2):108–112.
  28. Horosan L, Nistor DE, Ion A, et al. Understanding suicide. Discoveries. 2024;12(1):e183.
  29. Lu DY. Is Tau molecule regarded as a risk factor for human suicide? Int J Psychiatry. 2023;8(2):28.
  30. Lu DY, Zhu PP, Wu HY, et al. Human suicide risk and treatment study. CNS Agents Med Chem. 2018;18(3):206–212.
  31. Lu DY, Che JY, Wu HY, et al. Suicide risks and prevention: neuropathogenic study. Edeweiss Psychiatry. 2020;4(1):124.
  32. Mann JJ, Michel CA, Auerbach RP. Improving suicide prevention through evidence-based strategies: a systematic review. Am J Psychiatry. 2021;178(7):611–624.
  33. Lu DY. Human suicide: clinical treatment overview. J Psychol Clin Psychiatry. 2025;16(1):24–28.
  34. Lu DY, Che JY. Human suicide: risk factors and new perspective. J Psychol Clin Psychiatry. 2025;16(1):65–68.
  35. Lu DY, Zhu PP, Lu TR, et al. The suicidal risks and treatments: seeking medications from multi-disciplinary approaches. CNS Agents Med Chem. 2016;16(3):231–239.
  36. Lu DY, Lu TR. Drug discovery for suicide management. EC Pharmacol Toxicol. 2021;9(11):76–86.
  37. Eagles JM. Light therapy and seasonal affective disorder. Psychiatry. 2009;8(4):125–129.
  38. Lu DY, Wu HY, Lu TR. Human suicide: management landscape. Psychol J Res Open. 2024;6(3):1–2.
  39. Rutz W. Preventing suicide and premature death by education and treatment. J Affect Disord. 2001;62:123–129.
  40. Lu DY, Lu TR. Human suicide risk study and treatment: a mathematical approach. J Ment Disord Treat. 2018;4(2):161.
  41. Lu DY, Lu TR, Yarla NS. Human suicide study from mathematical approaches. Clin Biotechnol Microbiol. 2018;2(3):361–363.
  42. Huang DC, Yang MX, Wen X, et al. AI-driven drug discovery: accelerating the development of novel therapeutics in biopharmaceuticals. Int Med Sci Res J. 2024;4(8):882–899.
  43. Shinde PS, Pawar AY, Talele SG. The role of artificial intelligence in the pharmaceutical sector: a comprehensive analysis of its application from the discovery phase to industrial implementation. Int J Drug Deliv Technol. 2023;13(4):1578–1584.
  44. Dashpute SV, Pansare JJ, Deore YK, et al. Artificial intelligence and machine learning in the pharmaceutical industry. Int J Pharm Pharm Res. 2023;28(2):111–131.
Creative Commons Attribution License

©2025 Lu. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.